12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Resminostat: Interim Phase I/II data

Interim data from 15 patients in the dose-escalation Phase I portion of the open-label, German Phase I/II SHORE trial showed that oral resminostat in combination with FOLFIRI chemotherapy was generally well tolerated up to a once-daily dose of 600 mg for up to 33 weeks. There were some cases...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >